Event JSON
{
"id": "0a6e737f3dd63874e2c48ef6a4643f67d8a26aae5e5bf4b3ea11a3f23b4aae72",
"pubkey": "6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"created_at": 1739250274,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/incyte-stock-sinks-sales-forecast-194704008.html"
],
[
"subject",
"Incyte Stock Sinks as Sales Forecast for Key Drugs Falls Short"
],
[
"published_at",
"1739216824"
],
[
"image",
"https://s.yimg.com/ny/api/res/1.2/yGpH6JfLjEFqEyLKnwR1ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/investopedia_245/719a161872f1b45b18931a38663b00ee"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://s.yimg.com/ny/api/res/1.2/yGpH6JfLjEFqEyLKnwR1ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/investopedia_245/719a161872f1b45b18931a38663b00ee"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"Incyte's Q4 sales rose 16% year-over-year, topping estimates, but the company's adjusted earnings per share (EPS) of $1.43 came in 10 cents below expectations. The company's outlook for sales of its two biggest drugs, Jakafi and Opzelura, also fell short of expectations. Despite this, Incyte's shares are still up roughly 20% over the last 12 months."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqvap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aesst3mr8r\nhttps://s.yimg.com/ny/api/res/1.2/yGpH6JfLjEFqEyLKnwR1ig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/investopedia_245/719a161872f1b45b18931a38663b00ee\n\nhttps://finance.yahoo.com/news/incyte-stock-sinks-sales-forecast-194704008.html",
"sig": "35dc0b3a6360076b0e57969a7f20c28cb1e5382757736ba5b29f06fd4f8663cff3fd17b39dd9bd96a3fa5e711205ac33d05284e61cd23fdc4cd52cced095fdc1"
}